The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non–Clear-Cell Histology
Abstract
PURPOSE: To define outcome data for patients with metastatic renal cell carcinoma (RCC) with histology other than clear-cell type, including collecting duct (or medullary carcinoma), papillary, chromophobe, and unclassified histologies. PATIENTS AND METHODS: Sixty-four patients with metastatic non–clear-cell RCC histology were the subjects of this retrospective review. Included in the analysis were 22 (8%) of 286 patients from a clinical trials database, 19 of 1,166 patients from a surgery database, and 23 of 357 patients from a pathology database. RESULTS: The prevalent histology was collecting duct, present in 26 (41%) patients. The number of patients with chromophobe and papillary histologies was 12 (19%) and 18 (28%), respectively. Eight (12%) of the patients had tumors that could not be classified for specific tumor histology. Among the 43 patients treated with 86 systemic therapies, including 37 cytokine therapies, two patients (5%) were observed to have a partial response. The median overall survival time was 9.4 months (95% confidence interval, 8 to 14 months). The survival was longer for patients with chromophobe tumors compared with collecting duct or papillary histology, and this group included four patients with survival of greater than 3 years. CONCLUSION: RCC consists of a heterogeneous group of tumors including clear-cell, papillary, chromophobe, collecting duct, and unclassified cell types. Non–clear-cell histologies constitute less than 10% of patients in general populations of patients with advanced RCC treated on clinical trials. Metastatic non–clear-cell RCC is characterized by a resistance to systemic therapy and poor survival, with the survival for patients with chromophobe tumors longer than that for patients with metastatic collecting duct or papillary RCC. Treatment with novel agents on clinical trials is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Motzer, R. J., Bander, N. H., & Nanus, D. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609193351207 · Cited by 2,219
Self-citationSchmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
A POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMA
KATTAN, M. W., REUTER, V., MOTZER, R. J., KATZ, J., & RUSSO, P. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)66077-6 · Cited by 754
Self-citationRosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.8.622 · Cited by 639
SURGICAL MANAGEMENT OF RENAL TUMORS 4 CM. OR LESS IN A CONTEMPORARY COHORT
LEE, C. T., KATZ, J., SHI, W., THALER, H. T., REUTER, V. E., & RUSSO, P. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67793-2 · Cited by 638
Self-citationSYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
MOTZER, R. J., & RUSSO, P. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67889-5 · Cited by 603
Self-citation(1999) · The Lancet · doi:10.1016/s0140-6736(98)03544-2 · Cited by 601
Renal Medullary Carcinoma The Seventh Sickle Cell Nephropathy
Davis, C. J., Mostofi, F. K., & Sesterhenn, I. A. (1995) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199501000-00001 · Cited by 599
Novel mutations of the MET proto-oncogene in papillary renal carcinomas
Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., Lubensky, I., Neumann, H. P., Brauch, H., Decker, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202547 · Cited by 497
Pyrhönen, S., Salminen, E., Ruutu, M., Lehtonen, T., Nurmi, M., Tammela, T., Juusela, H., Rintala, E., Hietanen, P., & Kellokumpu-Lehtinen, P.-L. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2859 · Cited by 441
Renal Oncocytoma: A Reappraisal of Morphologic Features with Clinicopathologic Findings in 80 Cases
Amin, M. B., Crotty, T. B., Tickoo, S. K., & Farrow, G. M. (1997) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199701000-00001 · Cited by 346
RENAL CELL CARCINOMA: MANAGEMENT OF ADVANCED DISEASE
FIGLIN, R. A. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61897-4 · Cited by 266
Motzer, R. J., Murphy, B. A., Bacik, J., Schwartz, L. H., Nanus, D. M., Mariani, T., Loehrer, P., Wilding, G., Fairclough, D. L., Cella, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2972 · Cited by 264
Self-citationVogelzang, N. J., & Stadler, W. M. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01041-1 · Cited by 222
Contemporary approach to the classification of renal epithelial tumors.
Reuter, V. E., & Presti, J. C. (2000) · PubMed · Cited by 182
Self-citationWebb, C. P., Hose, C. D., Koochekpour, S., Jeffers, M., Oskarsson, M. K., Sausville, E. A., Monks, A. P., & Woude, G. F. V. (2000) · PubMed · Cited by 168
Phase II Trial of Thalidomide for Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Berg, W. J., Ginsberg, M. S., Russo, P., Vuky, J., Yu, R., Bacik, J., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.302 · Cited by 133
Self-citationPhase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
Motzer, R. J., Lyn, P., Fischer, P., LIANES, P., Ngo, R. L., Cordon‐Cardo, C., & O'Brien, J. P. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1958 · Cited by 77
Self-citationMotzer, R. J., Nanus, D. M., O’Moore, P. V., Scher, H. I., Bajorin, D. F., Reuter, V. E., Tong, W. P., Iversen, J., Louison, C., & Albino, A. P. (1992) · PubMed · Cited by 50
Self-citation
Cited by
Heng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133
Cohen, H. T., & McGovern, F. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043172 · Cited by 1,554
Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Bacik, J., Schwartz, L. H., Reuter, V., Russo, P., Marion, S., & Mazumdar, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.132 · Cited by 793
Self-citationPrognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience
Patard, J.-J., Leray, E., Rioux-Leclercq, N., Cindolo, L., Ficarra, V., Zisman, A., De La Taille, A., Tostain, J., Artibani, W., Abbou, C. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.055 · Cited by 754
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Gore, M. E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G. A., Oudard, S., Hariharan, S., Lee, S.-H., Haanen, J., Castellano, D., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70162-7 · Cited by 589
Metadata
- Authors
- Motzer, R. J., Bacik, J., Mariani, T., Russo, P., Mazumdar, M., & Reuter, V.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-05-01
- Volume
- 20
- Issue
- 9
- Pages
- 2376-2381
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2080679809
- Cited by
- 496
- References
- 20
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.